Download Poster: Overall Survival with Kisqali® plus Endocrine Therapy in Patients with Advanced Breast Cancer with Visceral Metastases 6
![Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-021-01415-9/MediaObjects/41416_2021_1415_Fig1_HTML.png)
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer
![Kaplan–Meier analysis of locally assessed progression-free survival in... | Download Scientific Diagram Kaplan–Meier analysis of locally assessed progression-free survival in... | Download Scientific Diagram](https://www.researchgate.net/publication/321195924/figure/fig2/AS:961363971149836@1606218440258/Kaplan-Meier-analysis-of-locally-assessed-progression-free-survival-in-patients-with-de.gif)
Kaplan–Meier analysis of locally assessed progression-free survival in... | Download Scientific Diagram
![Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753421015532-gr1.jpg)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect
![MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2019-0130/asset/images/medium/figure1.gif)
MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology
![ASCO 2022: AstraZeneca, Pfizer, Novartis Share Key Data on Breast Cancer Therapeutics - GeneOnline News ASCO 2022: AstraZeneca, Pfizer, Novartis Share Key Data on Breast Cancer Therapeutics - GeneOnline News](https://www.geneonline.com/wp-content/uploads/DESTINY-Breast04-Trial-e1654844085833.png)
ASCO 2022: AstraZeneca, Pfizer, Novartis Share Key Data on Breast Cancer Therapeutics - GeneOnline News
![Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups | npj Breast Cancer Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-021-00289-7/MediaObjects/41523_2021_289_Fig1_HTML.png)
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups | npj Breast Cancer
![ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).](https://larvolclin.s3.us-west-2.amazonaws.com/resize_162308040295527161060be3dd24570a.png)
ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
![Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0960977620301867-gr2c.jpg)
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect
![MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting - The ASCO Post MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting - The ASCO Post](https://ascopost.com/media/14021064/1-neven.jpg?anchor=center&mode=crop&width=400&height=300&rnd=133104961710000000)